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The development of robotic technology has facilitated the
application of minimally invasive techniques for the treatment
and evaluation of patients with early, advanced, and recurrent
cervical cancer. The application of robotic technology for
selected patients with cervical cancer and the data available
in the literature are addressed in the present review paper. The
robotic radical hysterectomy technique developed at the Mayo
Clinic Arizona is presented with data comparing 27 patients
who underwent the robotic procedure with 2 matched groups
of patients treated by laparoscopic (N = 31), and laparotomic
radical hysterectomy (N= 35). A few other studies confirmed
the feasibility and safety of robotic radical hysterectomy and
comparisons to either to the laparoscopic or open approach
were discussed. Based on data from the literature, minimally
invasive techniques including laparoscopy and robotics are
preferable to laparotomy for patients requiring radical hyste-
rectomy, with some advantages noted for robotics over laparo-
scopy. A prospective randomised trial is currently being per-
fomred under the auspices of the American Association of
Gyneoclogic Laparoscopists comparing minimally invasive
radical hysterectomy (laparoscopy or robotics) with laparotomy.
For early cervical cancer radical parametrectomy and fertility
preserving trachelectomy have been performed using robotic
technology and been shown to be feasible, safe, and easier to
perform when compared to the laparoscopic approach. Similar
benefits have been noted in the treatment of advanced and
recurrent cervical cancer where complex procedures such as
extraperitoneal paraortic lymphadenectomy and pelvic exentera-
tion have been required. Conclusion: Robotic technology better
facilitates the surgical approach as compared to laparoscopy for
technically challenging operations performed to treat primary,
early or advanced, and recurrent cervical cancer. Although
patient advantages are similar or slightly improved with robotics,
there are multiple advantages for surgeons.
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INTRODUCTION
The development of robotic technology has
facilitated the application of minimally invasive
techniques for the treatment and evaluation of
patients with early, advanced, and recurrent cer-
vical cancer. The use of a robotic system in preset
laboratory drills has been associated with faster
performance times, increased accuracy, enhanced
dexterity, faster suturing, and reduced number of
errors when compared to conventional laparo-
scopic instrumentation.
1 Complex operations, such
as radical hysterectomy, can be addressed in a
more efficient fashion and the skills to perform this
procedure are acquired not only in a shorter time
but by a larger number of laparotomy surgeons
who encountered difficulties with conventional
laparoscopy. The application of robotic technology




For early cervical cancer robotic and laparo-
scopic radical hysterectomy have been shown to
have advantages for patients over the laparotomy
approach in terms of blood loss, blood trans-
fusions, complications, and length of hospital
stay, with the exception of prolonged operating
times.
2-5 Similar recurrence and cure rates have
been reported when comparing the results of both
techniques.
2-5 However, a prospective randomized
trial comparing minimally invasive radical hyster-
ectomy (laparoscopy or robotics) with laparotomy
has never been performed but is being performed
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at present under the auspices of the American
Association of Gyneoclogic Laparoscopists.
6
Our surgical approach for the performance of
robotic radical hysterectomy has been described
elsewhere.
7 A summary of the important steps is
addressed here.
Technique
Operative set-up and instrumentation
Patients are placed in the semi-lithotomy
position. Four trocars are used: a 12-mm tran-
sumbilical optical trocar, two 8-mm robotic trocars,
and a 10-mm assistant trocar. The Trendelenburg
position is necessary until all bowels are out of the
pelvis to a maximum of 30 degrees. No uterine
manipulator is used but a vaginal probe (Apple
Medical, Marlborough, MA, USA) and a colpo-
occluder balloon (Rumi Colpo-occluder, Cooper
Medical, Trumbull, CT, USA).
The robotic column is placed between the
patient's feet. An EndoWrist PK grasper (Intuitive
Inc., Sunnyvale, CA, USA) and an EndoWrist
monopolar spatula (Intuitive Inc.) are used with
the left and right robotic arms, respectively. An
Endo Wrist Prograsper (Intuitive Inc.) is used in
the fourth robotic arm whenever used. An
EndoWrist needle holder (Intuitive Inc.) is used for
vaginal cuff closure switching the monopolar
spatula.
Surgical technique
The extent of paracervical resection of the
radical technique according to the Mayo classifi-
cation of radical hysterectomy has been described
elsewhere,
8 and is applied to our robotic techni-
que. After dissection of the paravesical and para-
rectal spaces, the external iliac nodes, the obtura-
tor nodes, the nodes of the hypogastric artery,
and common iliac nodal groups are removed
bilaterally using the PK grasper and monopolar
spatula.
The lateral parametrium is transected at the
origin of the branches from the internal iliac
artery and vein with successive applications of
the EnSeal vessel-sealing bipolar device (SurgRx,
Inc., Redwood city, CA, USA; Ethicon Endo-
Surgery, Inc.), to the level of the deep uterine
vein dorsally. This preserves the parasympathetic
pelvic splachnic nerves. The uterosacral ligaments
are transected with the EnSeal at the level of the
anterior rectal wall toward the upper-posterior
vaginal wall, which preserves the caudal portion
of the sympathetic nerves in that area. An addi-
tional portion of the sympathetics can be pre-
served if separated from the lateral portion of the
uterosacral ligaments.
Once the bladder is dissected from the cervix and
upper vagina, the ventral and dorsal portions of
the vesicouterine ligament are transected with the
EnSeal. With the ureter elevated, the paravaginal
tissues are divided with the EnSeal below the level
of transection of the lateral parametrium and
uterosacral ligament. The vagina is transected
circumferentially with the monopolar spatula and
the uterus is removed vaginally.
The vaginal cuff is closed with 2 continuous
sutures of 2-0 Vicryl precut at 15 cm and with a
fastened Lapra-Ty (Ethicon Endo Surgery, Cincin-
nati, OH, USA) at their end.
RESULTS
During the period of April 20, 2003 to September
16, 2006, a total of 523 patients underwent robotic
surgery for gynecologic conditions at the Mayo
Clinic Arizona. Among them, 27 patients under-
went robotic radical hysterectomy for the primary
treatment of gynecologic cancer. Our first radical
hysterectomy was performed on April 9, 2003.
These patients were compared to 2 matched
groups of patients (laparoscopy, N = 31, and
laparotomy, N = 35) by age, BMI, site and type of
malignancy, FIGO staging, uterine size, and type
of radical hysterectomy.
The mean operating time was significantly
longer for the laparoscopic (220.4 minutes) group
compared to both robotic (189.9 minutes) and
laparotomy (166.8 minutes) groups (p < 0.001). The
mean blood loss (443 mL; 133 mL; 208 respec-
tively), mean rate of blood loss (2.6 mL; 0.7 mL; 0.9
mL respectively), and mean length of hospital stay
(3.6 days; 1.7 days; 2.4 days, respectively) were
significantly higher for the laparotomy group
compared to both robotic and laparoscopic groups
(p < 0.05). There were no difference in the number
of lymph nodes, and intra or post-operativeRobotic Surgery for Cervical Cancer
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complications among the 3 groups.
At a mean length of follow up of 27.1 months
(range, 10 - 50 months), none of the patients with
cervical cancer have experienced recurrence.
Based on these and other data, laparoscopy and
robotics are preferable to laparotomy for the
treatment of early stage cervical cancer. Robotic
surgery offers a shorter operating time and nu-




The first published report regarding robotic
radical hysterectomy was in 2006.
9 In 2007, a pilot
case-control study designed to evaluate the feasi-
bility and efficacy of robotic-assisted laparoscopic
radical hysterectomy and bilateral pelvic lymph
node dissection for early cervical cancer was
reported in 7 consecutive patients, compared to 8
patients treated with conventional total laparo-
scopic radical hysterectomy.
10 There were no
statistically significant differences observed in the
2 groups in regards to operation time (241 vs 300
minutes), number of lymph nodes, and length of
resected parametrial tissue, whereas significantly
less bleeding (71 vs 160 mL) and shorter hospital
stay (4 vs 8 days) were described in the robotic-
assisted group (p < 0.05).
A retrospective clinical review of 10, stage IA2-
IB1 cervical cancer patients who underwent
robotic-assisted radical hysterectomy was pub-
lished by Kim YT et al. in February 2008. No
conversion to laparotomy was observed, mean
operative time was 207 minutes, and mean esti-
mated blood loss was 355 mL, the average number
of resected pelvic lymph nodes was 27.6, no
ureteral injuries or fistula complications were
described.
11 The authors concluded that robotic
radical hysterectomy for selected early cervical
cancer cases is feasible and associated with low
morbidity.
Fanning J et al. performed robotic radical
hysterectomies in 20 consecutive stage IA-IIA
cervical cancer patients.
12 Mean operative time was
6.5 hours, mean estimated blood loss was 300 mL,
the average number of pelvic lymph nodes was 18,
and all the patients went home on post-operative
day 1. Even though the operative time seems to
be long compared to other series, the authors
concluded that the improved vision and intra-
abdominal articulation of the robot provide an
advantage in performing the most difficult steps of
radical hysterectomy, such as unroofing and dis-
section of the distal ureter.
Nezhat FR et al. compared the intra-operative,
pathologic, and post-operative outcomes of robotic
radical hysterectomy to total laparoscopic radical
hysterectomy in 13 and 21 patients with early stage
cervical cancer, respectively. No statistical differ-
ences were observed regarding operative time (323
vs 318 minutes), estimated blood loss (157 vs 200
mL) and mean pelvic nodes count (25 vs 31).
13
There were no recurrences in either group with a
mean follow-up time of 12 months in the robotic
group and 29 months in the laparoscopic group.
Their conclusion was that robotic radical hyster-
ectomy appears to be equivalent to total laparosco-
pic radical hysterectomy with respect to operative
time, blood loss, hospital stay, and oncologic
outcome.
Boggess JF et al. recently published a case-
control study of robotic-assisted type III radical
hysterectomy (RHA) with pelvic lymph node
dissection performed in 51 patients compared with
49 patients who underwent open radical hyste-
rectomy (ORH).
14 There were significant differ-
ences between the groups with regard to operative
blood loss (p < 0.0001), operative time (p = 0.0002),
and lymph node retrieval (p = 0.0003), all of which
were in favor of the RAH cohort. Hospital stay for
RAH group was 1 day, compared with a 3.2-day
average hospitalization for the cohort with ORH.
The authors' conclusion was that robotic type III
radical hysterectomy with pelvic node dissection
is feasible and may be preferable over open radical
hysterectomy in patients with early-stage cervical
cancer.
The results described above confirmed similar
patient benefits as it has been shown with the
use of laparoscopy as compared to laparotomy
for cervical, endometrial, and colorectal cancer
patients.
15-22 However, while previous reports
demonstrated longer operating times for robotics,
the mean operating times for robotics and laparo-
tomy were similar in our hands, and significantlyJavier F. Magrina and Vanna L. Zanagnolo
Yonsei Med J Vol. 49, No. 6, 2008
shorter as compared to laparoscopy.
15 In addition,
as compared to laparoscopy, robotic patients
undergoing the radical technique had signifi-
cantly less blood loss and those who underwent
the modified radical technique had a significantly
shorter hospitalization. In summary, minimally
invasive techniques, laparoscopy, and robotics are
preferable to laparotomy for patients requiring
radical hysterectomy, with some advantages
noted for robotics over laparoscopy.
A phase III randomized clinical trial comparing
laparoscopic or robotic radical hysterectomy
(TLRH/TRRH) with abdominal radical hysterec-
tomy (TARH) in patients with early stage cervical
cancer is being performed under the auspices of
the AAGL.
6 The aim of the study is to show the
equivalence of the laparoscopic or robotic ap-
proach versus the abdominal approach following
a 2-phase protocol. In the first phase, 100 patients
will be randomized (1 : 1) to receive either TLRH/
TRRH or TARH, with the rate of enrollment
being the primary end point. In the second phase,
recruitment will be extended by another 640
patients in a 1 : 1 TLRH/TRRH : TARH allocation,
to determine equivalence with respect to disease-
free survival. Equivalence will be assumed if the
difference in disease-free survival does not exceed
7% at 4 years. Secondary outcomes will be treat-
ment-related morbidity, costs and cost effecti-
veness, patterns of recurrence, quality of life,
pelvic floor function, feasibility of intraoperative
sentinel node sampling, and overall survival. This
trial will be sufficiently powered to show the
equivalence of primary and secondary outcomes
for this patient population, which will allow
patients and health administrators to make an in-
formed choice of surgical alternatives in collabo-
ration with gynecologic oncology surgeons.
Robotic radical parametrectomy
Treatment options for patients with undia-
gnosed cervical cancer discovered incidentally on
a simple hysterectomy specimen include adjuvant
radiation therapy or radical parametrectomy,
which includes removal of the upper vagina, lateral
parametria, and regional lymph nodes. Tradition-
ally radical parametrectomy has been performed
by laparotomy, with few cases described by
laparoscopic-assisted vaginal or total laparoscopic
approach.
23-25
Ramirez PT et al. reported the first 5 patients
treated by robotic radical parametrectomy and
pelvic lymphadenectomy.
26 The median operative
time was 365 minutes, estimated blood loss was
100 mL, the median number of pelvic lymph nodes
was 14, and there were no conversion to laparo-
tomy. There was 1 intra-operative cystomy and 1
patient experienced 2 post-operative compli-
cations, a vesicovaginal fistula, and a lymphocyst.
The authors' concluded that robotic radical
parametrectomy and bilateral pelvic lymphadenec-
tomy is feasible and safe and can be performed
with an acceptable complication rate.
Robotic radical trachelectomy
Vaginal radical trachelectomy in conjunction
with laparoscopic pelvic lymphadenectomy to
preserve fertility in women with early cervical
cancer is now well established and considered to
be as safe as traditional radical hysterectomy
when strict selection criteria are met.
27-30 A few
cases of various extent of laparoscopy in con-
junction with a final vaginal approach and 1
case of total laparoscopic radical trachelectomy
have been described.
31-34 The first report of a
robotic radical trachelectomy for fertility sparing
in stage IB1 adenocarcinoma of the cervix was
published by Person J et al., who reported 2 cases
of robotic radical trachelectomy and pelvic
lymphadenectomy performed in 2 nullipaurous
women with early stage cervical cancer.
35 The
duration of the surgeries were 387 and 358
minutes, respectively. The long operative time
was justified by the authors as a product of the
novelty of the procedure and waiting time for
frozen section. No perioperative complications
were observed. Their conclusion was that robotic
radical trachelectomy is a safe and feasible alter-
native to a combined laparoscopic and vaginal
approach.
Geisler JP et al. in October 2008, published another
case report of a robotic radical trachelectomy in a
stage IB1 adenosarcoma of the cervix, operating
time was 172 minutes and the estimated blood loss
was 100 mL.
36Robotic Surgery for Cervical Cancer
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Advanced cervical cancer
Nodal dissection, transperitoneal and extraperitoneal
Laparoscopic pelvic and paraaotic lymph node
staging is widely used in patients with advanced
cervical cancer prior to initiation of primary
chemo-radiation therapy due to lack of sensitivity
of imaging techniques. This approach has been
shown to be feasible and safe.
37-39 An extended
pelvic and para-aortic lymphadenectomy can
reliably and safely be performed robotically in the
management of gynecological malignancies. The
robotic system aids in performing a meticulous
dissection and in adhering to sound oncologic
principles. For the robotic approach data are avail-
able for both pelvic and para-aortic lymphadenec-
tomy performed during staging procedure for
endometrial, cervical, or early ovarian cancers.
1,9-15,40
Extraperitoneal para-aortic laparoscopic lym-
phadenectomy is preferable to reduce the risk of
adhesions prior to chemioradiation treatments and
for obese patients where the transperitoneal
approach can be more difficult or impossible. Data
are available for the laparoscopic approach, both
in terms of safety and feasibility.
41-44 Recently,
Vergote I et al. reported on 5 patients with stage
IIb-IIIb cervical carcinoma undergoing robotic
retroperitoneal para-aortic lymphadenectomy. The
authors concluded the robotic procedure was
technically easier than the laparoscopic approach.
45
At the Mayo Clinic Arizona, a robotic extraperi-
toneal infrarenal aortic lymphadenectomy tech-
nique was developed in fresh-frozen cadavers and
successfully applied to patients, and will be the




Treatment of patients with recurrent cervical
carcinoma after initial primary surgery or chemo-
radiation is based on a single or combination of
treatment modalities such as radiotherapy, chemo-
therapy, and various surgical procedures.
47,48 Mini-
mally invasive surgery may improve the outcome
of patients with bulky residual tumors after
chemoradiation for locally advanced cervical
cancer and for lateral pelvic wall recurrence. In
case of central pelvic recurrence after surgery and
adjuvant radiation treatment, pelvic exenteration is
the only therapeutic approach with curative goals.
Women facing an exenterative procedure should
undergo a comprehensive evaluation to make sure
there is no evidence of unresectable or metastatic
disease that would make them unsuitable candi-
dates for exenteration. The laparoscopic approach
for a pre-treatment evaluation in patients with
recurrent cervical cancer has already shown to be
paramount to select adequate candidates for
exenterative procedure similarly a pre-exenteration
robotic evaluation can be easily performed.
49,50
Pruthi RS et al. recently described the technique
of robotic-assisted laparoscopic anterior pelvic
exenteration performed in 12 women for clinically
localized bladder cancer.
51 Nine patients under-
went ileal conduit diversion and 3 patients
underwent an orthotopic neobladder. In all cases,
the urinary diversion was performed extracor-
poreally. Mean operating room time was 4.6 hours
and the mean surgical blood loss was 221 mL.
Mean time to flatus was 1.9 days and 2.4 days to
bowel movement, and time to discharge 4.8 days.
There were 2 postoperative complications (17%) in
2 patients. The authors' initial experience with
robotic-assisted laparoscopic anterior pelvic exen-
teration appears to be favorable with acceptable
operative, pathologic, and short-term clinical out-
comes. However, the oncological outcomes of these
new, minimally invasive surgical approaches need
to be carefully verified through more experience
to adequately evaluate and validate these pro-
cedures as appropriate surgical and oncologic
options.
CONCLUSION
For technically challenging operations per-
formed to treat primary, early or advanced, and
recurrent cervical cancer, robotic technology facili-
tates the surgical approach better in comparison
to laparoscopy due to its steady 3-dimensional
visualization, instrumentation with articulating
tips, and an adaptive downscaling of the surgeons
movements without tremor. Although patient
advantages are similar or slightly improved with
robotics, there are multiple advantages for the
surgeons. The present randomized clinical trialJavier F. Magrina and Vanna L. Zanagnolo
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will most likely confirm the advantages of the
minimally invasive approach over laparotomy.
6
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